Signals, Powered By EquityPandit
Dishman Pharmaceuticals has got the Establishment Inspection Reports (EIR) from the USFDA for its Balva facility.
The company has said in a BSE filing that “The Balva facility was successfully inspected by the USFDA in July, 2016, which was intimated to the stock exchanges on July 09, 2016. In this regard, the Company has received the Establishment Inspection Report (EIR) from the US FDA for this facility on February 01, 2017. Thus, the company’s facilities in Balva, Naroda and Switzerland continue to be approved by the USFDA.”
